Neuphoria Therapeutics (NEUP) Cash & Current Investments (2020 - 2026)

Neuphoria Therapeutics (NEUP) has reported Cash & Current Investments for 7 consecutive years, with $19.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Current Investments rose 14.06% year-over-year to $19.4 million; the TTM figure through Mar 2026 stood at $19.4 million (up 14.06% YoY), while the FY2025 annual figure was $14.3 million, up 13.33% from the prior year.
• Cash & Current Investments slipped to $19.4 million in Q1 2026 per NEUP's latest filing, from $22.3 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $24.0 million in Q2 2022 and bottomed at $4.3 million in Q4 2024.
• Historically, Cash & Current Investments has averaged $13.4 million across 5 years, with a median of $12.6 million in 2024.
• Annual changes were most pronounced in 2024 — Cash & Current Investments tumbled 57.22% — and 2025, when it surged 412.13%.
• Neuphoria Therapeutics' Cash & Current Investments stood at $24.0 million in 2022, then sank by 57.76% to $10.2 million in 2023, then plunged by 57.22% to $4.3 million in 2024, then soared by 412.13% to $22.3 million in 2025, then slipped by 12.63% to $19.4 million in 2026.
• Business Quant data shows NEUP's Cash & Current Investments at $19.4 million in Q1 2026, $22.3 million in Q4 2025, and $13.7 million in Q3 2025.